Senolytics dasatinib and quercetin studied for safety and feasibility in secondary progressive MS.
This RCT examined whether senolytic therapy (dasatinib and quercetin given orally every two weeks for three months) is safe and feasible in adults aged 50-85 with secondary progressive MS who were not on disease-modifying therapy and had progressive symptoms. Participants were followed for one year to assess treatment effects on physical and cognitive function. No results of the trial are provided in this abstract.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 8, 2025 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 12 months
- Population
- Adults with secondary progressive multiple sclerosis (SPMS), aged 50-85 years, not currently taking MS disease-modifying therapy, with worsening MS symptoms
- Primary outcome
- Safety and feasibility of senolytic therapy in patients with secondary progressive MS
- Effect size
- —
- Significance
- Not reported
- Journal
- Ohio State University
- Published
- Dec 8, 2025
Sources
Primary source
- Ohio State University ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.